ClinicalTrials.gg
CompletedNCT05799157Updated May 8, 2025

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

A Phase 2 interventional study of VDMN-21 Patch Low Dose and VDMN-21 Patch High Dose in Verruca Vulgaris, Warts and Common Wart, sponsored by Veradermics, Inc.. Completed at 16 sites in United States. Open to participants aged 9 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Veradermics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
9 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.

Enrollment
15th of 58
153 · median 80
Started
2023
with 1 other
Phase 2
23 of 59
1 open now
Registered
50th of 59
by date

Among the 59 studies in Warts with a site in United States, this one is the 15th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2023, is one of 23 in phase 2, and was the 50th registered.

Warts

172 studies on the registry are indexed under Warts; 36 are open to participants now.

Browse Warts studies →

Open to participants now

7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Warts studies recruiting now, 10 (53%) set no upper age limit and 9 (47%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 9 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Warts with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris

Read the detailed description

Protocol 250-12951-201 is a planned Phase 2 study entitled "A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris". Eligible subjects will be randomized into one of the three treatment groups (high dose, low dose, vehicle).

03

Conditions studied

  • Verruca Vulgaris
  • Warts
  • Common Wart

Browse trials for

04

Who can participate

Ages eligible
9 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a male or non-pregnant female, 9 to 65 years of age.
  • Subject has provided written /assent.
  • Females must be , surgically sterile, or use an effective method of . Women of (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Baseline.
  • Subject has at least 1 and up to 8 common warts (verruca vulgaris),
  • Subject is willing to undergo test article therapy as directed, comply with study instructions (including availability to a smart phone or equivalent device for telehealth visit requirements), and commit to all follow-up visits for the duration of the study.
  • Subject is in good general health and free of any disease state or physical condition that might impair evaluation of the identified warts and/or treatment area or exposes the subject to an unacceptable risk by study participation.

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant, lactating, or is planning to become pregnant during the study.
  • Subject used or will use oral zinc and/or cimetidine within 30 days prior to enrollment or during the course of the study.
  • Subject has received 3 or more prior treatments to the Target Lesion without resolution.
  • Subject received any of the following therapies within the specified prior to Baseline in the treatment area of the Target Lesion

    1. LASER, light or other energy-based therapy (e.g., intense pulsed light [IPL], PDT; 12 weeks
    2. Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester [SADBE], etc.), retinoids, hydrogen peroxide; 12 weeks
    3. Cryotherapy, , electrodessication, curettage, antimetabolite therapy (e.g., 5- fluorouracil), cantharidin, or any other treatment that in the opinion of the Investigator may affect the Target Lesion; 6 weeks
    4. Over-the-counter (OTC) wart therapies, paring ± occlusion; 1 week
  • Subject has scars, tattoos, or other features that may interfere with the evaluation of the Target Lesion, in the opinion in the investigator.
  • Subject has a significant condition or is based on their medical condition (e.g., , , etc.), medication use, or other factors. Routine use of inhaled, intranasal or ophthalmologic during the study is allowed.
  • Subject has received systemic immunosuppressive therapy such as steroids, methotrexate, cyclosporine, tacrolimus, chemotherapy, etc. within in 4 weeks prior to Baseline.
  • Subject has any active malignancy or are undergoing treatment for any malignancy other than nonmelanoma skin cancer;
  • Subject has history of significant ophthalmologic inflammatory disease, including uveitis.
  • Subject is currently enrolled in an drug, biologic, or device study.
  • Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to Visit 1/Baseline.
  • Subject has a history of allergy or sensitivity to this antigen extract or similar products.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Treatment Group A (Low Dose)

    Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).

    Drug: VDMN-21 Patch Low Dose

  • Experimental
    Treatment Group B (High Dose)

    High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).

    Drug: VDMN-21 Patch High Dose

  • Placebo comparator
    Treatment Group C (Vehicle)

    Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).

    Drug: Vehicle Patch

Interventions

  • DrugVDMN-21 Patch Low Dose

    Microneedle patch containing 125 mcg of active drug

  • DrugVDMN-21 Patch High Dose

    Microneedle patch containing 250 mcg of active drug

  • DrugVehicle Patch

    Placebo microneedle patch containing no active drug (i.e., placebo)

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment period

    Complete clinical resolution is defined as the target lesion with area = 0.

    Time frame: Baseline up to Day 134

Other outcomes

  1. Proportion of subjects with complete clinical resolution of Target Lesion by visit

    Time frame: Days 22, 43, 64, 85, 106, and 134

  2. Proportion of subjects with complete clinical resolution of all the Non-Target Lesion(s) by visit

    Time frame: Days 22, 43, 64, 85, 106, and 134

07

Study locations

16 sites
  • Site 07
    Fort Smith, Arkansas 72916, United States
  • Site 16
    San Diego, California 92123, United States
  • Site 02
    Plainfield, Indiana 46168, United States
  • Site 13
    Louisville, Kentucky 40241, United States
  • Site 15
    Baton Rouge, Louisiana 70809, United States
  • Site 09
    New Brighton, Minnesota 55112, United States
  • Site 01
    Anderson, South Carolina 29621, United States
  • Site 06
    Greenville, South Carolina 29615, United States
  • Site 11
    Knoxville, Tennessee 37909, United States
  • Site 03
    Arlington, Texas 76011, United States
  • Site 04
    Austin, Texas 78759, United States
  • Site 10
    College Station, Texas 77845, United States
  • Site 12
    Houston, Texas 77056, United States
  • Site 05
    Pflugerville, Texas 78660, United States
  • Site 14
    Norfolk, Virginia 23502, United States
  • Site 08
    Spokane, Washington 99202, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Feb 2025, 23 months.

Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Apr 5, 2023
StartActual
Feb 28, 2023
Primary completionActual
Feb 25, 2025
CompletionActual
Feb 25, 2025
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05799157
Lead sponsor
Veradermics, Inc.
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Feb 28, 2023
Primary completion
Feb 25, 2025
Completion
Feb 25, 2025
Last update
May 8, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion